03 Aug 2026

CRC Research Update — August 03, 2026

Creator: The CRC Digest
Published: 2026-08-03T20:45:38Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

REGULATORY
FDA approves second blood test to help close colorectal cancer screening gap
The FDA has approved a second blood-based screening test for colorectal cancer, expanding options for patients who may avoid traditional colonoscopy. (AOL.com)
RESEARCH
AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapy
A post-hoc analysis of the phase III ARISTOTLE trial found that higher tumor cell density predicted improved survival in locally advanced rectal cancer patients receiving irinotecan-intensified neoadjuvant chemoradiotherapy; researchers developed a free online tool called Octopath where clinicians can upload biopsy slides for analysis. (The ASCO Post)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Financial and professional impacts persist for early-onset CRC survivors
A multicenter study across 7 academic medical centers found that patients diagnosed with colorectal cancer before age 50 experience lasting financial and professional instability, given their developmental stage in establishing careers and families. (Diseases of the Colon & Rectum)

Research continues to expand screening options and refine treatment for all stages of colorectal cancer.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest